- Home
- RDHL vs CNSP Comparison
RDHL vs CNSP Comparison
Compare RDHL & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDHL | CNSP |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | Israel | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 4.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | RDHL | CNSP |
|---|---|---|
| Price | $1.19 | $6.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 66.4K | 14.0K |
| Earning Date | 09-05-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,550,000.00 | N/A |
| Revenue This Year | $381.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 157.62 | N/A |
| 52 Week Low | $1.01 | $4.93 |
| 52 Week High | $7.00 | $114.00 |
Technical Indicators
Market Signals| Indicator | RDHL | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | 38.87 |
| Support Level | $1.15 | $7.01 |
| Resistance Level | $1.24 | $7.78 |
| Average True Range (ATR) | 0.05 | 0.60 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 48.75 | 8.86 |
Price Performance
Historical ComparisonAbout RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.